Close
Open Nav

Thank you for attending, see you in 2017!

 

Monday, October 17 | 1:00pm - 6:30pm

The BIO SPARK Showcase aims to provide an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding.

The BIO Investor Forum is historically well attended by the venture arms and business development units of major pharmaceutical companies, smaller specialty pharma/biotech companies looking to add to their pipelines, start-ups, and many early stage venture capital firms, making it the ideal setting for early stage assets from the university setting. Academics interested in partnering will present their programs and also have one-on-one discussions with interested parties. 

BIO Spark Showcase Presentation Schedule

Time

Spark Affiliate and Program

1:00 PM - 1:10 PM Welcome from SPARK Translational Research Program, Stanford Medicine
  • Daria Mochly-Rosen, PhD, Director
  • Mahima Agochiya, PhD, Business Development & Program Manager
1:10 PM - 1:30 PM Triursus Therapeutics & Stanford University SPARK
New Monoclonal Antibody Therapies to Improve Bone Marrow Transplantation
Everett Meyer
1:30 PM - 1:50 PM Monash University, Australia
Tanis21: IL-21 Superagonist for Immuno-oncology and Chronic Viral Infection
Di Yu 
1:50 PM - 2:10 PM Nanyang Technological University, Singapore
DotBio: Modular Domain Antibodies for Therapeutic Applications 
Ignacio Asial
2:10 PM - 2:30 PM SupremeCure Pharma Inc. & Si2C, Taiwan
SHP-1 Phosphatase Agonist for Hepatocellular Carcinoma
Kuen-Feng Chen
2:30 PM - 2:40 PM Break
2:40 PM - 3:00 PM University of Technology Sydney, Australia
Treatment and Prevention of Mesothelioma Using Zeolites
Tony George
3:00 PM - 3:20 PM University of Vermont
Development of Cymanquine, a Metallo-Chloroquine Derivative, for Cancer Care
Claire Verschraegen
3:20 PM - 3:40 PM Stanford University SPARK
p300/CBP Histone Acetyltransferase Inhibitors for Treatment of Cancer
Alex Loktev
3:40 PM - 4:00 PM National Taiwan University, Taiwan
A Novel Anti-MRSA Agent Without Detectable Resistance
Hao-Chieh Chiu
4:00 PM - 4:10 PM Break
4:10 PM - 4:30 PM Monash University–Hudson Institute of Medical Research, Australia
Amniotic Exosome Therapy
Rebecca Lim
4:30 PM - 4:50 PM Indiana University School of Medicine, Indiana Center for Biomedical Innovation
Disease Modifying Therapy for Pulmonary Arterial Hypertension
Jaipal Singh
4:50 PM - 5:10 PM National Taiwan University, Taiwan
RS-D7: New Chemical Entity with Positive Clinical Data in Human for White Space in Schizophrenia Treatment
Jane Tseng
5:10 PM - 5:30 PM Stanford University SPARK
Novel Therapeutics for Hyaluronan Inhibition
Paul Bollyky
5:30 PM - 6:30 PM Reception